Amino Innovations Expands Peptide Product Access with New U.S. Wholesale Program

The latest announcement is out from Pangea Natural Food, Inc. ( (TSE:PNGA) ).

Amino Innovations, a subsidiary of Pangea Wellness Inc., has launched a U.S. wholesale and B2B distribution program to expand access to its non-injectable peptide-based wellness products. This initiative introduces a comprehensive distribution model, providing clinics, wellness centers, and performance facilities with alternatives to traditional injectable therapies through products like oral capsules and topical creams. The program aims to enhance accessibility and customer experience while offering new revenue streams for partners, positioning Amino Innovations as a leader in the peptide wellness industry.

Spark’s Take on TSE:PNGA Stock

According to Spark, TipRanks’ AI Analyst, TSE:PNGA is a Underperform.

Pangea Natural Food, Inc. has substantial financial challenges, including negative margins and cash flows, which heavily impact its overall stock score. While technical indicators show some upward momentum, the stock is overbought, adding risk. The valuation remains unattractive due to negative earnings. Recent corporate events, such as acquisitions and financing, could provide future opportunities but do not counterbalance the current financial distress.

To see Spark’s full report on TSE:PNGA stock, click here.

More about Pangea Natural Food, Inc.

Pangea Wellness Inc. is a North American manufacturer specializing in clean-label foods and innovative wellness products. Through its subsidiary Amino Innovations, the company offers advanced, non-injectable peptide delivery systems that support recovery, cognitive function, and overall health.

Average Trading Volume: 124,220

Technical Sentiment Signal: Buy

Current Market Cap: C$5.6M

For an in-depth examination of PNGA stock, go to TipRanks’ Overview page.